BACKGROUND: The aim of this study was to assess the efficacy of choline-stabilized orthosilicic acid (ch-OSA) in patients with symptomatic knee osteoarthritis (OA). METHODS: In a multicenter, double-blind, placebo-controlled study, 211 patients with knee OA (Kellgren and Lawrence grade II or III) and moderate to moderately severe pain were randomly allocated to ch-OSA or placebo for 12 weeks. The primary outcome was the change in the WOMAC pain subscale from baseline to week 12. Secondary outcomes were changes from baseline to week 12 in WOMAC total, WOMAC stiffness, WOMAC physical function, Subject Global Assessment and levels of cartilage degradation biomarkers C-terminal telopeptide of collagen type II (CTX-II) and cartilage oligomeric matrix protein (COMP). Pre-specified subgroup analyses included the effect of gender. RESULTS: A total of 166 (120 women, 46 men) patients were included in the analysis (87 and 79 in the ch-OSA and placebo group, respectively). In the total study population, no differences were observed between the two treatment groups for the different outcomes but significant treatment x gender interactions were found. In men taking ch-OSA, a significant improvement in WOMAC total, WOMAC stiffness and WOMAC physical function as well as a lower increase in biomarker levels of cartilage degradation was observed, but not in women. The change in WOMAC pain showed a similar positive trend in men taking ch-OSA. CONCLUSION: After 12 weeks of treatment, no effect was found of ch-OSA in the total study population on clinical parameters and biomarkers, but a gender interaction was observed. In men, ch-OSA was found effective in reducing symptoms of knee OA, which was associated with a slight but significant reduction of biomarkers that are related to cartilage degradation. TRIAL REGISTRATION: The study was registered retrospectively: ISRCTN88583133 . Registration date: 2015-10-07.

Biomedical Research Institute Hasselt University Diepenbeek Belgium

Department of Pharmaceutical Sciences University of Antwerp Antwerp Wilrijk Belgium

Institute of Rheumatology Prague Czech Republic

Nábrežie 1 Krasku 4782 4 Piešťany Slovakia

Research and Development Bio Minerals NV Destelbergen Belgium

ReumaClinic Bretheistraat 149 Genk 3600 Belgium

Rheumatology Maastricht UMC Maastricht The Netherlands

Zobrazit více v PubMed

Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646–656. PubMed PMC

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. OsteoarthrCartil. 2007;15:981–1000. PubMed

Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr Cartil. 2011;19:515–542. doi: 10.1016/j.joca.2010.08.019. PubMed DOI PMC

Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635–646. doi: 10.7326/0003-4819-133-8-200010170-00016. PubMed DOI

Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377:2115–2126. doi: 10.1016/S0140-6736(11)60243-2. PubMed DOI

Lafeber FP, van Laar JM. Strontium ranelate: ready for clinical use as disease-modifying osteoarthritis drug? Ann Rheum Dis. 2013;72:157–161. doi: 10.1136/annrheumdis-2012-202453. PubMed DOI

Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res. 2013;65:703–711. doi: 10.1002/acr.21898. PubMed DOI PMC

Thysen S, Luyten FP, Lories RJ. Targets, models and challenges in osteoarthritis research. Dis Model Mech. 2015;8:17–30. doi: 10.1242/dmm.016881. PubMed DOI PMC

Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthr Cartil. 2005;13:769–781. doi: 10.1016/j.joca.2005.04.014. PubMed DOI

Guermazi A, Hunter DJ, Roemer FW. Plain radiography and magnetic resonance imaging diagnostics in osteoarthritis: validated staging and scoring. J Bone Joint Surg Am. 2009;91(Suppl 1):54–62. doi: 10.2106/JBJS.H.01385. PubMed DOI

van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthr Cartil. 2010;18:605–612. doi: 10.1016/j.joca.2010.01.012. PubMed DOI

Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyere O, Chapurlat R, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013;72:1756–1763. doi: 10.1136/annrheumdis-2013-203726. PubMed DOI PMC

Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthr Cartil. 2006;14:723–727. doi: 10.1016/j.joca.2006.04.001. PubMed DOI

Spector TD, Calomme MR, Anderson SH, Clement G, Bevan L, Demeester N, et al. Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial. BMC Musculoskelet Disord. 2008;9:85. doi: 10.1186/1471-2474-9-85. PubMed DOI PMC

Barel A, Calomme M, Timchenko A, De Paepe K, Demeester N, Rogiers V, et al. Effect of oral intake of choline-stabilized orthosilicic acid on skin, nails and hair in women with photodamaged skin. Arch Dermatol Res. 2005;297:147–153. doi: 10.1007/s00403-005-0584-6. PubMed DOI

Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis. 2011;34:3–15. doi: 10.1007/s10545-010-9088-4. PubMed DOI

Toohey JI. Homocysteine toxicity in connective tissue: theories, old and new. Connect Tissue Res. 2008;49:57–61. doi: 10.1080/03008200801913742. PubMed DOI

Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29:1039–1049. doi: 10.1002/art.1780290816. PubMed DOI

Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16:494–502. doi: 10.1136/ard.16.4.494. PubMed DOI PMC

Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–1840. PubMed

Leys C, Ley C, Klein O, Bernard P, Licata L. Detecting outliers: do not use standard deviation around the mean, use absolute deviation around the median. J Exp Soc Psychol. 2013;49:764–766. doi: 10.1016/j.jesp.2013.03.013. DOI

Ziegler D, Pritchett YL, Wang F, Desaiah D, Robinson MJ, Hall JA, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007;30:664–669. doi: 10.2337/dc06-2009. PubMed DOI

Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) Ann Rheum Dis. 2003;62:1145–1155. doi: 10.1136/ard.2003.011742. PubMed DOI PMC

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16:137–162. doi: 10.1016/j.joca.2007.12.013. PubMed DOI

Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64:465–474. doi: 10.1002/acr.21596. PubMed DOI

McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22:363–388. doi: 10.1016/j.joca.2014.01.003. PubMed DOI

Geusens P, Lems W. Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis. Ther Clin Risk Manag. 2008;4:337–344. doi: 10.2147/TCRM.S1209. PubMed DOI PMC

Thaler R, Agsten M, Spitzer S, Paschalis EP, Karlic H, Klaushofer K, et al. Homocysteine suppresses the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation. J Biol Chem. 2011;286:5578–5588. doi: 10.1074/jbc.M110.166181. PubMed DOI PMC

Zhang Q, Li H, Zhang Z, Yang F, Chen J. Serum metabolites as potential biomarkers for diagnosis of knee osteoarthritis. Dis Markers. 2015;2015:684794. PubMed PMC

Jugdaohsingh R, Watson AI, Pedro LD, Powell JJ. The decrease in silicon concentration of the connective tissues with age in rats is a marker of connective tissue turnover. Bone. 2015;75:40–48. doi: 10.1016/j.bone.2015.02.004. PubMed DOI PMC

Calomme M, Geusens P, Demeester N, Behets GJ, D’Haese P, Sindambiwe JB, et al. Partial prevention of long-term femoral bone loss in aged ovariectomized rats supplemented with choline-stabilized orthosilicic acid. Calcif Tissue Int. 2006;78:227–232. doi: 10.1007/s00223-005-0288-0. PubMed DOI

Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173] Arthritis Res Ther. 2005;7:R625–R633. doi: 10.1186/ar1716. PubMed DOI PMC

Lories RJ, Luyten FP. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol. 2011;7:43–49. doi: 10.1038/nrrheum.2010.197. PubMed DOI

McAlindon TE, Snow S, Cooper C, Dieppe PA. Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. Ann Rheum Dis. 1992;51:844–849. doi: 10.1136/ard.51.7.844. PubMed DOI PMC

O’Connor MI, Hooten EG. Breakout session: gender disparities in knee osteoarthritis and TKA. Clin Orthop Relat Res. 2011;469:1883–1885. doi: 10.1007/s11999-010-1743-4. PubMed DOI PMC

Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci. 2006;26:5777–5785. doi: 10.1523/JNEUROSCI.5223-05.2006. PubMed DOI PMC

Hanna FS, Teichtahl AJ, Wluka AE, Wang Y, Urquhart DM, English DR, et al. Women have increased rates of cartilage loss and progression of cartilage defects at the knee than men: a gender study of adults without clinical knee osteoarthritis. Menopause. 2009;16:666–670. doi: 10.1097/gme.0b013e318198e30e. PubMed DOI

van Spil WE, Drossaers-Bakker KW, Lafeber FP. Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis. 2013;72:29–36. doi: 10.1136/annrheumdis-2011-201177. PubMed DOI

Roman-Blas JA, Castaneda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther. 2009;11:241. doi: 10.1186/ar2791. PubMed DOI PMC

Calvo E, Castaneda S, Largo R, Fernandez-Valle ME, Rodriguez-Salvanes F, Herrero-Beaumont G. Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthr Cartil. 2007;15:69–77. doi: 10.1016/j.joca.2006.06.006. PubMed DOI

Wang CJ, Huang CY, Hsu SL, Chen JH, Cheng JH. Extracorporeal shockwave therapy in osteoporotic osteoarthritis of the knee in rats: an experiment in animals. Arthritis Res Ther. 2014;16:R139. doi: 10.1186/ar4601. PubMed DOI PMC

Reginster JY, Kvasz A, Bruyere O, Henrotin Y. Is there any rationale for prescribing hormone replacement therapy (HRT) to prevent or to treat osteoarthritis? Osteoarthr Cartil. 2003;11:87–91. doi: 10.1053/joca.2002.0872. PubMed DOI

Kwan Tat S, Lajeunesse D, Pelletier JP, Martel-Pelletier J. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol. 2010;24:51–70. doi: 10.1016/j.berh.2009.08.004. PubMed DOI PMC

European Medicines Agency (EMA). Recommendation to restrict the use of Protelos/Osseor (strontium ranelate). EMA/258269/2013. 2013. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/04/WC500142507.pdf. Accessed 25 Apr 2013.

European Food Safety Authority (EFSA) Scientific opinion of the panel on food additives and nutrient sources added to food on choline-stabilised orthosilicic acid added for nutritional purposes to food supplements following a request from the European Commission. EFSA J. 2009;948:1–23.

Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R, Chevalier X, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis. 2013;72:179–186. doi: 10.1136/annrheumdis-2012-202231. PubMed DOI PMC

Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martin-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56:555–567. doi: 10.1002/art.22371. PubMed DOI

Geusens P, Chapurlat R, Schett G, Ghasem-Zadeh A, Seeman E, de Jong J, et al. High-resolution in vivo imaging of bone and joints: a window to microarchitecture. Nat Rev Rheumatol. 2014;10:304–313. doi: 10.1038/nrrheum.2014.23. PubMed DOI

Zobrazit více v PubMed

ISRCTN
ISRCTN88583133